Now that Bio­gen’s ad­u­canum­ab team and the FDA’s Bil­ly Dunn have been bat­tered by a gamut of an­gry ex­perts, the an­a­lysts are weigh­ing in

On Fri­day af­ter­noon, some an­gry and deeply dis­turbed ex­perts on the FDA ad­vi­so­ry pan­el slapped down Bio­gen $BI­IB and the FDA’s Bil­ly Dunn in a way that’s nev­er been seen be­fore dur­ing an ad­comm meet­ing. Then the an­a­lysts’ au­top­sies start­ed to ar­rive, dis­sect­ing how a dri­ve to gain ex­perts’ sup­port for the Alzheimer’s drug ad­u­canum­ab turned in­to a bloody rout, with a near-unan­i­mous vote at the end maul­ing the FDA’s po­si­tion on ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.